Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PRCP | P42785 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7268303 | 1.00 | L3MBTL1 (0.57) | L3MBTL1PRCPDPP7HTR2CHTR2B | |
| SCHEMBL17676963 | 0.94 | L3MBTL1 (0.54) | L3MBTL1PRCPDPP7HTR2CHTR2B | |
| SCHEMBL1983142 | 0.94 | L3MBTL1 (0.54) | L3MBTL1PRCPDPP7HTR2CHTR2B | |
| SCHEMBL495672 | 0.94 | L3MBTL1 (0.54) | L3MBTL1PRCPDPP7HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6860843 | 0.93 | L3MBTL1 (0.53) | L3MBTL1PRCPDPP7HTR2CHTR2B | |
| SCHEMBL15373851 | 0.88 | L3MBTL1 (0.54) | L3MBTL1PRCPDPP7TSHRALDH1A1 | |
| SCHEMBL26501818 | 0.88 | L3MBTL1 (0.54) | L3MBTL1PRCPDPP7TSHRALDH1A1 | |
| SCHEMBL27284993 | 0.79 | PRCP (0.45) | L3MBTL1PRCPDPP7HTR2CHTR2B | |
| SCHEMBL13306379 | 0.79 | PRCP (0.47) | L3MBTL1PRCPDPP7HTR2CHTR2B | |
| SCHEMBL22221409 | 0.79 | PRCP (0.47) | L3MBTL1PRCPDPP7HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1062536-A | Retroviral protease inhibitors from 3-chloro-2-chloromethyl-1-propylene derived | AMERICAN CYANAMID CO (US) | 1992-07-08 | — | — | CN | claimed |
| EP-0492136-A2 | Retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene | AMERICAN CYANAMID COMPANY (US) | 1992-07-01 | — | — | EP | claimed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-8293757-B2 | 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| US-8288540-B2 | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2012-10-16 | — | — | US | disclosed |
| US-8288540-B2 | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2012-10-16 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050004230-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2005-01-06 | — | — | US | disclosed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-6506759-B1 | Method for treating HIV-related AIDS comprising administering an effective amount of a composition N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in | MONSANTO COMPANY | 2003-01-14 | — | — | US | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-6127372-A | FOR TREATMENT OR PREVENTION OF VIRAL DISEASES, ESPECIALLY AIDS OR HIV | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0749421-B1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMA (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1995024385-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-09-14 | — | — | WO | disclosed |
| CN-1062536-A | Retroviral protease inhibitors from 3-chloro-2-chloromethyl-1-propylene derived | AMERICAN CYANAMID CO (US) | 1992-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | L3MBTL1 1588/4885PRCP 2198/4885DPP7 3064/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | L3MBTL1 2124/4885PRCP 2254/4885DPP7 2662/4885 |
| US-20050004230-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | L3MBTL1 798/4885PRCP 37/4885DPP7 92/4885 |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | FYN, LCK, ERBB2 | L3MBTL1 3713/4885PRCP 3643/4885DPP7 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.